Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY21 results · Oct–Dec 2020
Procter & Gamble Health reported revenue from operations of ₹240.22 crore (up 1.5% from Q3 FY20) and net profit of ₹67.88 crore (up 77.6% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 240.22 | 236.77 | +1.5% | 263.97 | −9.0% |
| Other income | 5.72 | 6.06 | −5.6% | 6.72 | −14.9% |
| Total income | 245.94 | 242.82 | +1.3% | 270.69 | −9.1% |
| Profit before tax | 86.43 | 50.80 | +70.2% | 77.22 | +11.9% |
| Net profit for the period | 67.88 | 38.21 | +77.6% | 59.26 | +14.5% |
| EPS, basic (₹) | 40.90 | 23.02 | +77.7% | 35.70 | +14.6% |
| Net margin (%) | 28.3 | 16.1 | 22.4 |
Standalone
- Filed with BSE
- 11 Feb 2021, 15:15 IST
- Board meeting
- 10 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE